Purpose or Objective: Gastrointestinal (GI) toxicity is a sideeffect induced by whole pelvis intensity modulated radiotherapy (WP-IMRT), affecting importantly patients' quality of life. The aim of this study was to identify predictors of diarrhea in a cohort of chemo-naÏf patients treated with WP-IMRT after prostatectomy.
Material and Methods:
The Inflammatory Bowel Disease questionnaire (IBDQ) was used to assess the degree of GI symptoms after WP-IMRT, investigating 4 distinct areas: bowel and systemic symptoms, emotional and social functions. This study focused on the most clinically relevant item 5 relative to the bowel domain, in order to evaluate the frequency of liquid defecation. Patient-reported scores at baseline, at RT mid-point and end, and every 3 months after RT end were prospectively collected . The responses are scored on a 7-point scale where 7 corresponds to the best function and 1 to the worst. Clinical/dosimetric data in 115 patients treated with adjuvant (n=65) or salvage (n=50) WPRT in a single Institute were available (static field IMRT:19; VMAT:55; Tomotherapy:41). Dose-volume histograms (DVHs) for intestinal loops and sigmoid colon were calculated. The 25th percentile of the score variation between baseline and half/end RT was considered as end-point ( ∆ -IBDQ5≤-3). Associations between diarrhea and clinical/DVH parameters were assessed by logistic uni-and backward multi-variable analyses. A previously introduced method based on DVH differences between patients with/without diarrhea toxicity was used to select the most discriminative DVH parameters.
Results: No significant correlation emerged for sigmoid colon, then the analysis was focused on intestinal loops. Patients without basal score and with ∆ -IBDQ5≤-3 were excluded from the analysis: 23/77 pts showed acute GI toxicity. At univariate analysis, volumes receiving 5 to 40Gy (V5-V40) were correlated with ∆ -IBDQ5≤-3 (p<0.03). Multivariate analysis confirmed a leading role of dosimetric variables, while no significant correlation for clinical parameters was found. Best cut-off values (assessed by ROC) discriminating patients with/without ∆ -IBDQ5≤-3 were: V20<250cc, V30<150cc and V40<90cc. The overall incidence equal to 10% and 50% resulted for the group of patients with DVH parameters lower/higher than thresholds, respectively (p=0.0028, OR=4.9, AUC=0.68).
Conclusion:
Low-medium IMRT doses to intestinal loops were correlated to diarrhea symptom at half/end of RT. This study proposed new dose volume constraints, that may be used to prevent much radiation-induced GI morbidity.
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Biological modelling to identify proton therapy candidates in focal boosting of prostate tumours J. Pedersen Purpose or Objective: MRI-based focal tumour boosting is currently under clinical investigation for prostate cancer patients, e.g. in the FLAME trial. These highly conformal, focal dose distributions can be difficult to achieve with photons, depending on the size and location of the boost volume (i.e. proximity to critical organs at risk). Selected patients might therefore be candidates for proton therapy. In previous work we have established an MRI-based tumour control probability (TCP) model. Combined with published rectum and bladder normal tissue complication probability (NTCP) models we have in this study explored the use of biological (TCP and NTCP) models to identify prostate cancer patients that might be suitable candidates for proton therapy if treated according to FLAME-like trial protocols.
Material and Methods: CT scans of seven patients from a prospective trial in our institution were used for planning. To obtain realistic boost geometries, MRI-based index tumours from a different cohort were used (matched on prostate volume), propagated with rigid registration on the prostate volume. VMAT plans (Eclipse, Varian Medical Systems) with and without a boost to the index lesion (95 Gy / 35 fx) were created; both plans delivered a conventional dose (77 Gy / 35 S808 ESTRO 35 2016 _____________________________________________________________________________________________________ fx) to the non-involved prostate. Planning constraints used were based on institutional procedures as well as from the FLAME trial, with small modifications in the boost plans. The dose distributions (with/without boost) were used to calculate the TCP and NTCP values for each patient. The TCP model used apparent diffusion coefficient maps to estimate cell densities while the NTCP models used were the conventional Lyman model for the rectum (late rectal bleeding grade >= 2; Rad. Onc, 73, 21-32, 2004) and the Poisson LQ model for the bladder (contracture; Ågren PhD thesis, 1995).
Results:
The TCP increased from a median (range) of 0.45 (0.08-0.83) with the conventional approach to 1.0 (no range) with the focal boost. While there were only minor differences in the rectum NTCPs with vs. without the boost there were considerable differences in the NTCP for the bladder for two of the patients (more than a doubling of the NTCP with the boost; Table 1 ). These two patients had the index lesion that was closest to the bladder.
Conclusion:
We have established a biological modelling based method to identify prostate cancer patients where the focal boost cannot be achieved with state of the art photonbased treatment without a considerable increase in the NTCPs. Further work will consider the feasibility of proton planning, given both inter-and intra-fractional organ motion patterns.
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